Omalizumab as add‐on therapy in a patient with severe asthma and OSA

Obstructive sleep apnoea (OSA) syndrome, the most frequent sleep‐disordered breathing, is a comorbidity of asthma, whose prevalence covers about 49.5% of asthmatic adult patients. A 61‐year‐old female patient, affected by severe allergic asthma and obesity, started treatment with omalizumab and unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Scioscia, Giulia, Buonamico, Enrico, Foschino Barbaro, Maria Pia, Lacedonia, Donato, Sabato, Roberto, Carpagnano, Giovanna Elisiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006716/
https://www.ncbi.nlm.nih.gov/pubmed/32055401
http://dx.doi.org/10.1002/rcr2.518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006716/
https://www.ncbi.nlm.nih.gov/pubmed/32055401
http://dx.doi.org/10.1002/rcr2.518

Ejemplares similares